4564 Stock Overview
Engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
OncoTherapy Science, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥49.00 |
52 Week High | JP¥64.00 |
52 Week Low | JP¥15.00 |
Beta | 0.44 |
11 Month Change | 63.33% |
3 Month Change | 206.25% |
1 Year Change | 58.06% |
33 Year Change | -44.32% |
5 Year Change | -54.21% |
Change since IPO | -96.33% |
Recent News & Updates
Shareholder Returns
4564 | JP Biotechs | JP Market | |
---|---|---|---|
7D | 25.6% | 4.3% | -2.1% |
1Y | 58.1% | -2.4% | 6.1% |
Return vs Industry: 4564 exceeded the JP Biotechs industry which returned -2.4% over the past year.
Return vs Market: 4564 exceeded the JP Market which returned 6.1% over the past year.
Price Volatility
4564 volatility | |
---|---|
4564 Average Weekly Movement | 30.9% |
Biotechs Industry Average Movement | 12.2% |
Market Average Movement | 6.3% |
10% most volatile stocks in JP Market | 9.9% |
10% least volatile stocks in JP Market | 3.3% |
Stable Share Price: 4564's share price has been volatile over the past 3 months.
Volatility Over Time: 4564's weekly volatility has increased from 17% to 31% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 54 | Junichi Shimada | www.oncotherapy.co.jp |
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer.
OncoTherapy Science, Inc. Fundamentals Summary
4564 fundamental statistics | |
---|---|
Market cap | JP¥12.88b |
Earnings (TTM) | -JP¥1.19b |
Revenue (TTM) | JP¥562.00m |
22.9x
P/S Ratio-10.8x
P/E RatioIs 4564 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4564 income statement (TTM) | |
---|---|
Revenue | JP¥562.00m |
Cost of Revenue | JP¥1.32b |
Gross Profit | -JP¥760.00m |
Other Expenses | JP¥430.00m |
Earnings | -JP¥1.19b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.53 |
Gross Margin | -135.23% |
Net Profit Margin | -211.74% |
Debt/Equity Ratio | 0% |
How did 4564 perform over the long term?
See historical performance and comparison